Press Releases 2010

Sabinsa Granted Forskolin Solubility Patent In China

December 15, 2010 0 Comments

The State Intellectual Property Office of the People's Republic of China has granted Sabinsa a patent entitled: "Process for Preparing Water Soluble Diterpenes and Their Applications." The innovation developed by Sabinsa and protected in China by this patent involves making the forskolin molecule water soluble by approximately 6000 times.

Sabinsa also holds patents on this process in USA, Eurasia, India, Philippines, Mexico, New Zealand, Singapore, South Africa, and Uzbekistan.

Forskolin solubility vastly increases the range of applications. Dr. Lakshmi Prakash, Sabinsa VP of Innovation & Business Development, said "Aqueous formulation facilitates the safe and effective use of forskolin as a natural ophthalmic drug in the management of glaucoma (approved in India), as well as in dermatological and related applications."

Forskolin is an extract prepared from the herb Coleus forskohlii, a member of the mint family of plants that grows wild in some parts of India. In some areas people grow it and use the roots to make pickle. In recent years, Coleus forskohlii has gained importance as the only source of Forskolin, a bioactive molecule with multiple applications in health and wellness, made possible due largely to research initiatives by Sabinsa.

This recent patent is the 66th in Sabinsa’s sizeable worldwide Intellectual Property portfolio. Additionally, Sabinsa has over 50 pending patent applications worldwide. The company continues to demonstrate its commitment to keeping the spirit of innovation alive in the industry, through sustained intellectual property creation and protection efforts.

ABOUT SAMI LABS

Sami Labs is a research oriented multinational health science company, which is a leading producer of nutraceuticals, cosmeceuticals, standardised herbal extracts, fine chemicals, specialty chemicals and probiotics.

CERTIFICATES

CONTACT US

Disclaimer

US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.

JavaScript is currently disabled.Please enable it for a better experience of Jumi.